Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission

Caseiro, Marcos Montani

doi:10.1590/S0036-46652006000200011

Abstracts

Hepatitis C virus (HCV) infection is an important public health issue worldwide. It is estimated that over 170 million people are infected with the virus. The present study reports six cases in which patients did not respond to combination therapy with pegylated interferon and ribavirin. However, after the addition of thalidomide to the therapy, the patients presented negative RNA PCR. The use of thalidomide combined with pegylated interferon and ribavirin for the treatment of hepatitis C is described here for the first time in the related literature.

Hepatitis C; Thalidomide

A infecção pelo vírus da Hepatite C (HCV) representa um importante problema de saúde pública no mundo, estima-se que mais de 170 milhões de pessoas estejam infectadas. Relatamos o encontro de 6 pacientes não respondedores à associação de Interferon Peguilado e Ribavirina que negativaram seu PCRRNA após a associação com talidomida. Trata-se do primeiro relato desta associação no tratamento da hepatite C encontrado na literatura.

CASE REPORT

Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission

Tratamento de hepatite C crônica em pacientes não respondedores, com a associação interferon peguilado, ribavirina e talidomida. Relato de seis casos

Marcos Montani Caseiro

Professor Pós-Graduação, Saúde Coletiva, UNISANTOS & UNILUS, Santos, SP, Brasil

^{Correspondence to} Correspondence to: Prof. Dr. Marcos Montani Caseir Av. Pinheiro Machado 678, ap. 94 11075-002 Marapé, Santos, São Paulo, Brasil mcaseiro@uol.com.br

SUMMARY

Hepatitis C virus (HCV) infection is an important public health issue worldwide. It is estimated that over 170 million people are infected with the virus. The present study reports six cases in which patients did not respond to combination therapy with pegylated interferon and ribavirin. However, after the addition of thalidomide to the therapy, the patients presented negative RNA PCR. The use of thalidomide combined with pegylated interferon and ribavirin for the treatment of hepatitis C is described here for the first time in the related literature.

Key words: Hepatitis C; Thalidomide.

RESUMO

A infecção pelo vírus da Hepatite C (HCV) representa um importante problema de saúde pública no mundo, estima-se que mais de 170 milhões de pessoas estejam infectadas. Relatamos o encontro de 6 pacientes não respondedores à associação de Interferon Peguilado e Ribavirina que negativaram seu PCRRNA após a associação com talidomida. Trata-se do primeiro relato desta associação no tratamento da hepatite C encontrado na literatura.

INTRODUCTION

The World Health Organization has estimated that there are 170 million people infected with Hepatitis C (HCV), which means that this infection is currently one of the most important public health issues worldwide⁴⁰. In 2001, there were around 1.4 million deaths caused by chronic liver diseases, among which 796,000 were caused by cirrhosis and 616,000 were caused by primary liver cancer (hepatocarcinoma). Twenty percent (280,000) of the total number of deaths were probably due to HCV infection²¹.

HCV infection is the primary cause of death in patients with chronic liver diseases worldwide^2,17,21,40. Combination therapy with pegylated interferon (IFNp) and ribavirin is currently the only available treatment for HCV approved by the Food and Drug Administration (FDA). This therapy is given for 24 weeks for genotypes 2 and 3, and for 48 weeks for genotype 1. Patients with genotype 1 undergoing IFNp-alfa-2b and ribavirin combination therapy achieve a sustained viral response (SVR) rate of 42%. Patients with genotypes 2 and 3 achieve an SVR rate of 82%⁴⁶. SVR rates in patients undergoing IFN-alfa-2a and ribavirin combination therapy are 46% and 76%, respectively^27,33,46.

The success rate of the treatment is not yet optimal and, considering the potential complications related to the long-term chronicity of HCV infection, it is imperative that we explore other treatment options. Thalidomide has several properties as a sedative-hypnotic, immunomodulatory, anti-inflammatory and antiangiogenic drug. Initially, it was indicated for nausea and caused human teratogenicity in pregnant women. Currently, it has been indicated for the treatment of cutaneous manifestations of erythema nodosum leprosum and has been investigationally used in combination with anticancer drugs to treat several types of carcinoma^{11,30,31,36,49,53,63,70,83}. There exists no published evidence that it has ever been tested in patients with chronic hepatitis C.

CASE REPORT

A male patient with chronic HCV infection, aged 44 years, with positive HCV antibodies identified in November 1996, and with unknown exposure to HCV, sought the medical center for clinical assessment on October 12, 1999. His liver function test showed alanine aminotransferase (ALT) 86 U/L, aspartate aminotransferase (AST) 178 U/L, and initial viremia was determined by HCV RNA of 340,463 U/mL (genotype 1a). Liver biopsy showed structural lesion (level 3) and steatosis.

In May 2001, the patient began therapy for HCV infection with weekly injections of IFN 3,000,000 U and ribavirin, for a total of 12 months. At the end of this treatment, HCV RNA was 1,309,317 U/mL, with ALT 151 U/L and AST U/L 272, which defined a non-responsive case. The patient was then referred to our service for reevaluation. As of October 2002, 1.5 µg/kg of IFNp alfa-2b once a week and 500 mg of ribavirin b.i.d. were administered to the patient for a total of 12 weeks. In January 2003, the viral load test showed HCV RNA of 2,126,000 U/mL and the patient complained of multiple ulcers, pain and had difficulty to eat. No response to local therapy or anesthetics and other medications was observed. In addition to IFN and ribavirin, a dose of 100 mg of thalidomide was prescribed b.i.d. for 30 days to treat the patient's mouth ulcers. At the follow-up appointment, one month later, the patient presented remission of the symptoms, and reported that the ulcers had disappeared in one week. His liver function test showed a decrease in AST (32 U/L) and ALT (40 U/L). Thalidomide administration was maintained for 30 days. In May 2003, the HCV RNA viral load was undetectable and in August 2003, the qualitative polymerase chain reaction (PCR) was negative, as well as in October, at the end of the treatment.

After this case, five other patients who presented no decrease in HCV viral load after 12 weeks of weekly treatment with 1.5 µg/kg of IFNp alfa-2b and 500 mg of ribavirin b.i.d. were treated with the same dose of thalidomide for 30 days. Four patients presented negative HCV PCR and one patient, who weighed 130 kg, had a decrease in HCV viral load of 1 log at the follow-up appointment 30 days after thalidomide use. Five patients presented sustained virologic response (SVR) at 48 weeks and 72 weeks.

DISCUSSION

Various therapeutic approaches have been reported for the treatment of hepatitis C in patients with no response to previous treatment combining IFN (conventional or pegylated) and ribavirin. Among these are the combination of IFN alpha + ribavirin + amantadine^{5,22,74,75,84}, IFN alpha + phlebotomy^24,26,56,68, IFN alpha + prednisolone^32,73, IFN alpha + cimetidine, IFN alpha + N-acetylcysteine^42,54 , IFN alpha and vitamin E^43,45,57,67. In addition to these, other adjuvant therapies include Levorin, glycyrrhizine^{10,28,39,41,52,55}, ursodeoxycholic acid^{12,14,23,59,60}, Maxamine⁷, pentoxifylline, Isoprinosine^61,80,87, colchicine^5,25,64,65, histamine³⁴, IL-10^1,18,44, IL-12^{29,35,76,85,86}, IL-2^{8,13,37,66,72}, IFN gamma^9,16,69, granulocyte colony-stimulating factor (G-CSF)^47,78,81, granulocyte-microphage colony-stimulating factor (GM-CSF)^48,58,77, and thymosin alpha 1^3,4,38,51,62. None of these approaches has proved more effective than IFNp and ribavirin combination therapy. The present study described the action of thalidomide and IFNp + ribavirin combination therapy. The use of thalidomide against various pathologies is well known^{11,30,31,36,49,53,63,70,82,83}. However, no studies have reported its use in HCV treatment. Various hypotheses can be formulated with regard to the efficacy of thalidomide, for instance, as an immunomodulatory, anti-inflammatory agent which inhibits TNF-alpha⁵⁰, or even the effects of thalidomide on lymphocytes, increasing interferon gamma secretion⁷⁹. Nevertheless, various questions remain. It is still unknown whether thalidomide has any effect on viral replication; whether it acts on the modulation of cytokines which act on the inflammatory process of liver diseases caused by HCV; and whether it is necessary to combine thalidomide with pegylated interferon and ribavirin. Other questions to consider are the appropriate dose of thalidomide; the duration of treatment; and the time to initiate treatment. Only a randomized clinical trial can provide us with the answers. We have already begun a pilot trial which will soon allow us to present more consistent data.

Received: 30 March 2005

Accepted: 5 October 2005

References

1. ABBAS, Z.E.T. MOATTER - Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels. J. Pak. med. Ass., 53: 59-62, 2003.
2. ALTER, M.J.; KUHNERT, W.L. & FINELLII, L. - Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. M.M.W.R., 52(RR 03): 1-16, 2003.
3. ANDREONE, P.; CURSARO, C.; GRAMENZI, A. et al. - A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver, 16: 207-210, 1996.
4. ANDREONE, P.; GRAMENZI,A.; CURSARO, C. et al. - Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J. viral Hepatitis, 11: 69-73, 2004.
5. ANGELICO, M.; CEPPARULO,M.; ANGELICO, F. et al. - A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Aliment. Pharmacol. Ther., 19: 339-347, 2004.
6. ANGELICO, M.; CEPPARULO, M.; BARLATTANI, A. et al. - Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment. Pharmacol. Ther., 14: 1459-1467, 2000.
7. BARNARD, D.L. - Pegasys (Hoffmann-La Roche). Curr. Opin. invest. Drugs, 2: 1530-1538, 2001.
8. BARREIROS, A.P.; SCHLAAK, J. F.; GERKEN, G. et al. - Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin. Europ. J. clin. Invest., 33: 628-629, 2003.
9. BATTEGAY, M.; HOLDENER, M.; NAEF, M. & WERNIL, M. - Human immunodeficiency and hepatitis C virus coinfection influenced by interferon-gamma. Immunol. Lett., 71: 141-142, 2000.
10. BEAN, P. - The use of alternative medicine in the treatment of hepatitis C. Amer. clin Lab., 21: 19-21, 2002.
11. BERGER, T.G.; HOFFMAN,C. & THIEBERG, M.D. - Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J. Amer. Acad. Derm., 33: 837-838, 1995.
12. BOUCHER, E.; GUYADER, D.; JACQUELINET, S. et al. - Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Digest. Liver Dis., 32: 29-33, 2000.
13. BOZKAYA, H.; BOZDAYI,A.M.; ASLAN, N. et al. - Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection, 28: 309-313, 2000.
14. CHEN, W.; LIU, J. & GLUUD, C. - Bile acids for viral hepatitis. Cochrane Database Syst. Rev., (2): CD003181, 2003.
15. COMBE, B. - Thalidomide: new indications? Joint Bone Spine, 68: 582-587, 2001.
16. DANSAKO, H.; NAGANUMA,A.; NAKAMURA, T. et al. - Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res., 97: 17-30, 2003.
17. DEUFFIC-BURBAN, S.; WONG,J.B.; VALLERON, A.J. et al. - Comparing the public health burden of chronic hepatitis C and HIV infection in France. J. Hepat., 40: 319-326, 2004.
18. DHARANCY, S.; CANVA, V.; GAMBIEZ, L.; PARIS, J.C. & DESREUMAUX, P. - Hepatic deficiency of interleukin 10 in chronic hepatitis C. Gastroenterology, 119: 1411-1412, 2000.
19. DIGGLE, G.E. - Thalidomide: 40 years on. Int. J. clin. Pract., 55: 627-631, 2001.
20. DOLEV, E. - The thalidomide story and its lessons. Harefuah., 140: 663-667, 2001.
21. EL-SERAG, H.B. - Hepatocellular carcinoma: an epidemiologic view. J. clin. Gastroent., 35 (suppl. 2): S72-78, 2002.
22. ENGLER, S.; FLECHTENMACHER,C.; WIEDEMANN, K.H. et al. - Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J. viral Hepatitis, 11: 60-68, 2004.
23. FABBRI, C.; MARCHETTO, S.; PEZZOLI, A. et al. - Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Europ. J. Gastroent. Hepat., 12: 511-515, 2000.
24. FARGION, S.; FRACANZANI,A.L.; ROSSINI, A. et al. - Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Amer. J. Gastroent., 97: 1204-1210, 2002.
25. FLOREANI, A.; LOBELLO, S.; BRUNETTO, M.; ANELONI, V. & CHIARAMONTE, M. - Colchicine in chronic hepatitis B: a pilot study. Aliment. Pharmacol. Ther., 12: 653-656, 1998.
26. FONG, T.L.; HAN,S.H.; TSAI, N.C. et al. - A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J. Hepat., 28: 369-374, 1998.
27. FRIED, M.W.; SHIFFMAN,M.L.; REDDY, K.R. et al. - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl. J. Med., 347: 975-982, 2002.
28. FUJIOKA, T.T.; KONDOU, T.; FUKUHARA, A. et al. - Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepat. Res., 26: 10-14, 2003.
29. GATELY, M.K. - Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. J. viral Hepatitis, 4 (suppl. 1): S33-S39, 1997.
30. GEORGHIOU, P.R. & KEMP, R.J. - HIV-associated oesophageal ulcers treated with thalidomide. Med. J. Aust., 152: 382-383, 1990.
31. GORIN, I.; VILETTE, B.; GEHANNO, P. & ESCANDE, J.P. - Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet, 335: 1343, 1990.
32. GUILERA, M.; FORNS,X.; TORRAS, X. et al. - Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. J. Hepat., 33: 135-141, 2000.
33. HADZIYANNIS, S.J.; SETTE Jr., H.; MORGAN, T.R. et al. - Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. intern. Med., 140: 346-355, 2004.
34. HELLSTRAND, K.; BRUNE, M.; MELLQUIST, V.H. et al. - Histamine and the response to IFN-alpha in chronic hepatitis C. J. Interferon Cytokine Res., 18: 21-22, 1998.
35. IL-12 for hepatitis C. Treatmentupdate, 11: 2-3, 1999.
36. KAPLAN, G. - Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology, 191: 564-568, 1994.
37. KASPRZAK, A.; ZABEL, M.; BICZYSKO, W. et al. - Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J. Histochem. Cytochem., 52: 29-38, 2004.
38. KULLAVANUAYA, P.; TREEPRASERTSUK, S.; THONG NGAM, D. et al. - The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J. med Ass. Thailand, 84 (suppl.): S462-S468, 2001.
39. KUMADA, H. - Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 62: 94-100, 2002.
40. LAUER, G.M. & WALKER, B.D. - Hepatitis C virus infection. New Engl. J. Med., 345: 41-52, 2001.
41. LIU, J.; MANHEIMER, E.; TSUTANI, K. & GLUUD, C. - Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Amer. J. Gastroent., 98: 538-544, 2003.
42. LOGUERCIO, C.; TUCCILLO, C.; CAPORASO, N. et al. - Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. Liver, 18: 166-172, 1998.
43. LOOK, M.P.; GERARD, A.; RAO, G.S. et al. - Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res., 43: 113-122, 1999.
44. LOUIS, H.; LE MOINE, O.; GOLDMAN, M. & DEVIERE, J. - Modulation of liver injury by interleukin-10. Acta Gastro-enterol. belg., 66: 7-14, 2003.
45. MAHMOOD, S.; YAMADA, G.; NIIYAMA, G. et al. - Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic. Res., 37: 781-785, 2003.
46. MANNS, M.P.; McHUTCHISON, J.G.; GORDON, S.C. et al. - Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958-965, 2001.
47. MARTIN, J.; NAVAS,S.; QUIROGA, J.A. & CARRENO, V. - Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine, 8: 313-317, 1996.
48. MARTIN, J.; QUIROGA,J.A.; NAVAS, S.; PARDO, M. & CARRENO, V. - Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine, 11: 267-273, 1999.
49. MATTHEWS, S.J. & McCOY, J.A.. - Thalidomide: a review of approved and investigational uses. Clin Ther., 25: 342-395, 2003.
50. MEIERHOFER, C.; DUNZENDORFER, S. & WIEDERMAN, C.J. - Theoretical basis for the activity of thalidomide. BioDrugs, 15: 681-703, 2001.
51. MOSCARELLA, S.; BUZZELLI, G.; ROMANELLI, R.G. et al. - Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver, 18: 366-369, 1998.
52. MUKHAMEDOV, N.B.; INOIATOVA, F.I.; ARIPOV, A.N. & ARIPOV, O.A. - Combined therapy of chronic hepatitis C in children with phosphogliv. Biomed. Khim., 49: 105-109, 2003.
53. NASCA, M.R.; MICALI, G.; CHEIGH, N.H.; WEST, L.E. & WEST, D.P. - Dermatologic and nondermatologic uses of thalidomide. Ann. Pharmacother., 37: 1307-1320, 2003.
54. NERI, S.; IERNA, D.; ANTOCI, S. et al. - Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva med., 42: 187-192, 2000.
55. OKUNO, T.; ARAI,K. & SHINDO, M. - Efficacy of interferon combined glycyrrhizin therapy in patients with interferon-resistant chronic hepatitis C. Nippon Rinsho, 53: 1022-1025, 1995.
56. ORTIZ, V.; OLASO,V.; LOPEZ VIEDMA, B. et al. - The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study. Gastroent. Hepat., 22: 122-126, 1999.
57. OTA, Y.; SASAGAWA, T.; SUZUKI, K. et al. - Vitamin E supplementation increases polyunsaturated fatty acids of RBC membrane in HCV-infected patients. Nutrition, 20: 358-363, 2004.
58. OU-YANG, P.; HWANG, L.H.; TAO, M.H.; CHIANG, B.L. & CHEN, D.S. - Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J. med. Virol., 66: 320-328, 2002.
59. PORCARO, G.; SANNINO, C.; MASTROIANNI, M. et al. - Ursodeoxycholic acid in the therapy of chronic hepatitis after treatment with interferon. Minerva med., 91: 141-145, 2000.
60. POUPON, R.E.; BONNAND, A.M.; QUENEAU, P.E. et al. - Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scand. J. Gastroent., 35: 642-649, 2000.
61. PROHASKA, W. & KLEESIEK, K. - Treatment of chronic hepatitis C with inosine pranobex. Lancet, 338: 390-391, 1991.
62. RASI, G.; PIERIMARCHI,P.; SINIBALDI-VALLEBONA, P.; COLELLA, F. & GARACI, E. - Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. Immunopharmacol., 3: 1169-1176, 2003.
63. REYES-TERAN, G.; SIERRA-MADERO, J.G.; MARTINEZ DEL CERRO, V. et al. - Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. Aids, 10: 1501-1507, 1996.
64. RHODEN, E.L.; PEREIRA-LIMA,J.; RHODEN, C.R. et al. - The role of colchicine in prevention of hepatic cirrhosis induced by carbon tetrachloride. Hepatogastroenterology, 46: 1111-1115, 1999.
65. ROCKEY, D.C. - Hepatic fibrogenesis and hepatitis C. Semin. Gastrointest. Dis., 11: 69-83, 2000.
66. ROLLIER, C.; DEPLA, E.; DREXHAGE, J.A. et al. - Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol., 78: 187-196, 2004.
67. ROSSI, S.J. & WRIGHT, T.L. - New developments in the treatment of hepatitis C. Gut, 52: 756-757, 2003.
68. SARTORI, M.; ANDORNO,S.; RIGAMONTI, C. & BOLDORINI, R. - Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig. Liver Dis., 33: 157-162, 2001.
69. TAKAHARA, T.; SUGIYAMA, K.; ZHANG, L.P. et al. - Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepat. Res., 28: 146-154, 2004.
70. Thalidomide and wasting. Posit. aware, 4: 5, 1995.
71. Thalidomide for diarrhea. GMHC Treat Issues, 10: 9, 1996.
72. THIBAULT, V.; DELAUGERRE, C.; CALVEZ, V. et al. - Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. Hepatology, 35: 238-239, 2002.
73. THIELE, D.L.; DUCHARME,L.; CUNNINGHAM, M.R. et al. - Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Amer. J. Gastroent., 91: 300-308, 1996.
74. THULUVATH, P.J.; MAHESHWARI, A.; MEHDI, J. et al. - Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut, 53: 130-135, 2004.
75. THULUVATH, P.J.; PANDE, H. & MAYGERS, J. - Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig. Dis. Sci., 48: 594-597, 2003.
76. TILLMANN, H.L. & MANNS, M.P. - GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res., 52: 83-90, 2001.
77. TSAI, N.C.; SHIMODA, N.; WONG, L. et al. - A novel treatment of patients with chronic hepatitis C. Hawaii med. J., 58: 85-88, 1999.
78. VAN THIEL, D.H.; FARUKI, H.; FRIEDLANDER, L. et al. - Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology, 42: 907-912, 1995.
79. VERBON, A.; JUFFERMANS, N.P.; SPEELMAN, P. et al. - A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob. Agents Chemother., 44: 2286-2290, 2000.
80. WALKER, M.P.; APPLEBY, T.C.; ZHONG, W.; LAU, J.Y. & HONG, Z. - Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir. Chem. Chemother., 14: 1-21, 2003.
81. WRIGHT, H.I.; GAVALER, J.S.; BADDOUR, N. & VAN THIEL, D.H. - Granulocyte colony stimulating factor (G-CSF) combined with alpha-interferon for the treatment of liver allograft recipients with viral hepatitis. J. Hepat., 21: 915-916, 1994.
82. WU, K.L. & SONNEVELD, P. - Thalidomide: new uses for an old drug. Ned. Tijdschr. Geneeskd., 146: 1438-1441, 2002.
83. YOULE, M.; CLARBOUR, J.; FARTHING, C. et al. - Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Brit. med. J., 298: 432, 1989.
84. YOUNOSSI, Z.M.; MULLEN, K.D.; HODNICK, S. et al. - Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. J. clin. Gastroent., 36: 427-430, 2003.
85. ZEUZEM, S. & CARRENO, V. - Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res., 52: 181-188, 2001.
86. ZEUZEM, S.; HOPF, U.; CARRENO, V. et al. - A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology, 29: 1280-1287, 1999.
87. ZHOU, S.; LIU, R.; BAROUDY, B.M.; MALCOLM, B.A. & REYES, G.R. - The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology, 310: 333-342, 2003.

Correspondence to:

Prof. Dr. Marcos Montani Caseir

Av. Pinheiro Machado 678, ap. 94

11075-002 Marapé, Santos, São Paulo, Brasil

mcaseiro@uol.com.br

Publication Dates

Publication in this collection
08 May 2006
Date of issue
Apr 2006

History

Received
30 Mar 2005
Accepted
05 Oct 2005

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

[1] 1. ABBAS, Z.E.T. MOATTER - Interleukin (IL) 1beta and IL-10 gene polymorphism in chronic hepatitis C patients with normal or elevated alanine aminotransferase levels. J. Pak. med. Ass., 53: 59-62, 2003.

[2] 2. ALTER, M.J.; KUHNERT, W.L. & FINELLII, L. - Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. M.M.W.R., 52(RR 03): 1-16, 2003.

[3] 3. ANDREONE, P.; CURSARO, C.; GRAMENZI, A. et al. - A double-blind, placebo-controlled, pilot trial of thymosin alpha 1 for the treatment of chronic hepatitis C. Liver, 16: 207-210, 1996.

[4] 4. ANDREONE, P.; GRAMENZI,A.; CURSARO, C. et al. - Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J. viral Hepatitis, 11: 69-73, 2004.

[5] 5. ANGELICO, M.; CEPPARULO,M.; ANGELICO, F. et al. - A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapy. Aliment. Pharmacol. Ther., 19: 339-347, 2004.

[6] 6. ANGELICO, M.; CEPPARULO, M.; BARLATTANI, A. et al. - Unfavourable effects of colchicine in combination with interferon-alpha in the treatment of chronic hepatitis C. Aliment. Pharmacol. Ther., 14: 1459-1467, 2000.

[7] 7. BARNARD, D.L. - Pegasys (Hoffmann-La Roche). Curr. Opin. invest. Drugs, 2: 1530-1538, 2001.

[8] 8. BARREIROS, A.P.; SCHLAAK, J. F.; GERKEN, G. et al. - Interleukin-2 has no additional therapeutic efficacy in the retreatment of patients with chronic hepatitis C that had not responded to interferon-alpha plus ribavirin. Europ. J. clin. Invest., 33: 628-629, 2003.

[9] 9. BATTEGAY, M.; HOLDENER, M.; NAEF, M. & WERNIL, M. - Human immunodeficiency and hepatitis C virus coinfection influenced by interferon-gamma. Immunol. Lett., 71: 141-142, 2000.

[10] 10. BEAN, P. - The use of alternative medicine in the treatment of hepatitis C. Amer. clin Lab., 21: 19-21, 2002.

[11] 11. BERGER, T.G.; HOFFMAN,C. & THIEBERG, M.D. - Prurigo nodularis and photosensitivity in AIDS: treatment with thalidomide. J. Amer. Acad. Derm., 33: 837-838, 1995.

[12] 12. BOUCHER, E.; GUYADER, D.; JACQUELINET, S. et al. - Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients. Digest. Liver Dis., 32: 29-33, 2000.

[13] 13. BOZKAYA, H.; BOZDAYI,A.M.; ASLAN, N. et al. - Circulating IL-2 and IL-10 in chronic active hepatitis C with respect to the response to IFN treatment. Infection, 28: 309-313, 2000.

[14] 14. CHEN, W.; LIU, J. & GLUUD, C. - Bile acids for viral hepatitis. Cochrane Database Syst. Rev., (2): CD003181, 2003.

[15] 15. COMBE, B. - Thalidomide: new indications? Joint Bone Spine, 68: 582-587, 2001.

[16] 16. DANSAKO, H.; NAGANUMA,A.; NAKAMURA, T. et al. - Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. Virus Res., 97: 17-30, 2003.

[17] 17. DEUFFIC-BURBAN, S.; WONG,J.B.; VALLERON, A.J. et al. - Comparing the public health burden of chronic hepatitis C and HIV infection in France. J. Hepat., 40: 319-326, 2004.

[18] 18. DHARANCY, S.; CANVA, V.; GAMBIEZ, L.; PARIS, J.C. & DESREUMAUX, P. - Hepatic deficiency of interleukin 10 in chronic hepatitis C. Gastroenterology, 119: 1411-1412, 2000.

[19] 19. DIGGLE, G.E. - Thalidomide: 40 years on. Int. J. clin. Pract., 55: 627-631, 2001.

[20] 20. DOLEV, E. - The thalidomide story and its lessons. Harefuah., 140: 663-667, 2001.

[21] 21. EL-SERAG, H.B. - Hepatocellular carcinoma: an epidemiologic view. J. clin. Gastroent., 35 (suppl. 2): S72-78, 2002.

[22] 22. ENGLER, S.; FLECHTENMACHER,C.; WIEDEMANN, K.H. et al. - Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J. viral Hepatitis, 11: 60-68, 2004.

[23] 23. FABBRI, C.; MARCHETTO, S.; PEZZOLI, A. et al. - Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients. Europ. J. Gastroent. Hepat., 12: 511-515, 2000.

[24] 24. FARGION, S.; FRACANZANI,A.L.; ROSSINI, A. et al. - Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Amer. J. Gastroent., 97: 1204-1210, 2002.

[25] 25. FLOREANI, A.; LOBELLO, S.; BRUNETTO, M.; ANELONI, V. & CHIARAMONTE, M. - Colchicine in chronic hepatitis B: a pilot study. Aliment. Pharmacol. Ther., 12: 653-656, 1998.

[26] 26. FONG, T.L.; HAN,S.H.; TSAI, N.C. et al. - A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J. Hepat., 28: 369-374, 1998.

[27] 27. FRIED, M.W.; SHIFFMAN,M.L.; REDDY, K.R. et al. - Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl. J. Med., 347: 975-982, 2002.

[28] 28. FUJIOKA, T.T.; KONDOU, T.; FUKUHARA, A. et al. - Efficacy of a glycyrrhizin suppository for the treatment of chronic hepatitis C: a pilot study. Hepat. Res., 26: 10-14, 2003.

[29] 29. GATELY, M.K. - Interleukin-12: potential clinical applications in the treatment of chronic viral hepatitis. J. viral Hepatitis, 4 (suppl. 1): S33-S39, 1997.

[30] 30. GEORGHIOU, P.R. & KEMP, R.J. - HIV-associated oesophageal ulcers treated with thalidomide. Med. J. Aust., 152: 382-383, 1990.

[31] 31. GORIN, I.; VILETTE, B.; GEHANNO, P. & ESCANDE, J.P. - Thalidomide in hyperalgic pharyngeal ulceration of AIDS. Lancet, 335: 1343, 1990.

[32] 32. GUILERA, M.; FORNS,X.; TORRAS, X. et al. - Pre-treatment with prednisolone does not improve the efficacy of subsequent alpha interferon therapy in chronic hepatitis C. J. Hepat., 33: 135-141, 2000.

[33] 33. HADZIYANNIS, S.J.; SETTE Jr., H.; MORGAN, T.R. et al. - Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. intern. Med., 140: 346-355, 2004.

[34] 34. HELLSTRAND, K.; BRUNE, M.; MELLQUIST, V.H. et al. - Histamine and the response to IFN-alpha in chronic hepatitis C. J. Interferon Cytokine Res., 18: 21-22, 1998.

[35] 35. IL-12 for hepatitis C. Treatmentupdate, 11: 2-3, 1999.

[36] 36. KAPLAN, G. - Cytokine regulation of disease progression in leprosy and tuberculosis. Immunobiology, 191: 564-568, 1994.

[37] 37. KASPRZAK, A.; ZABEL, M.; BICZYSKO, W. et al. - Expression of cytokines (TNF-alpha, IL-1alpha, and IL-2) in chronic hepatitis C: comparative hybridocytochemical and immunocytochemical study in children and adult patients. J. Histochem. Cytochem., 52: 29-38, 2004.

[38] 38. KULLAVANUAYA, P.; TREEPRASERTSUK, S.; THONG NGAM, D. et al. - The combined treatment of interferon alpha-2a and thymosin alpha 1 for chronic hepatitis C: the 48 weeks end of treatment results. J. med Ass. Thailand, 84 (suppl.): S462-S468, 2001.

[39] 39. KUMADA, H. - Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. Oncology, 62: 94-100, 2002.

[40] 40. LAUER, G.M. & WALKER, B.D. - Hepatitis C virus infection. New Engl. J. Med., 345: 41-52, 2001.

[41] 41. LIU, J.; MANHEIMER, E.; TSUTANI, K. & GLUUD, C. - Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Amer. J. Gastroent., 98: 538-544, 2003.

[42] 42. LOGUERCIO, C.; TUCCILLO, C.; CAPORASO, N. et al. - Determination of plasma alpha-glutathione S-transferases in patients with HCV-related chronic infection: its significance and possible clinical relevance. Liver, 18: 166-172, 1998.

[43] 43. LOOK, M.P.; GERARD, A.; RAO, G.S. et al. - Interferon/antioxidant combination therapy for chronic hepatitis C: a controlled pilot trial. Antiviral Res., 43: 113-122, 1999.

[44] 44. LOUIS, H.; LE MOINE, O.; GOLDMAN, M. & DEVIERE, J. - Modulation of liver injury by interleukin-10. Acta Gastro-enterol. belg., 66: 7-14, 2003.

[45] 45. MAHMOOD, S.; YAMADA, G.; NIIYAMA, G. et al. - Effect of vitamin E on serum aminotransferase and thioredoxin levels in patients with viral hepatitis C. Free Radic. Res., 37: 781-785, 2003.

[46] 46. MANNS, M.P.; McHUTCHISON, J.G.; GORDON, S.C. et al. - Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet, 358: 958-965, 2001.

[47] 47. MARTIN, J.; NAVAS,S.; QUIROGA, J.A. & CARRENO, V. - Recombinant human granulocyte colony-stimulating factor reduces hepatitis C virus replication in mononuclear cells from chronic hepatitis C patients. Cytokine, 8: 313-317, 1996.

[48] 48. MARTIN, J.; QUIROGA,J.A.; NAVAS, S.; PARDO, M. & CARRENO, V. - Modulation by biologic response modifiers of hepatitis C virus antigen-independent cytokine secretion in blood mononuclear cells. Cytokine, 11: 267-273, 1999.

[49] 49. MATTHEWS, S.J. & McCOY, J.A.. - Thalidomide: a review of approved and investigational uses. Clin Ther., 25: 342-395, 2003.

[50] 50. MEIERHOFER, C.; DUNZENDORFER, S. & WIEDERMAN, C.J. - Theoretical basis for the activity of thalidomide. BioDrugs, 15: 681-703, 2001.

[51] 51. MOSCARELLA, S.; BUZZELLI, G.; ROMANELLI, R.G. et al. - Interferon and thymosin combination therapy in naive patients with chronic hepatitis C: preliminary results. Liver, 18: 366-369, 1998.

[52] 52. MUKHAMEDOV, N.B.; INOIATOVA, F.I.; ARIPOV, A.N. & ARIPOV, O.A. - Combined therapy of chronic hepatitis C in children with phosphogliv. Biomed. Khim., 49: 105-109, 2003.

[53] 53. NASCA, M.R.; MICALI, G.; CHEIGH, N.H.; WEST, L.E. & WEST, D.P. - Dermatologic and nondermatologic uses of thalidomide. Ann. Pharmacother., 37: 1307-1320, 2003.

[54] 54. NERI, S.; IERNA, D.; ANTOCI, S. et al. - Association of alpha-interferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva med., 42: 187-192, 2000.

[55] 55. OKUNO, T.; ARAI,K. & SHINDO, M. - Efficacy of interferon combined glycyrrhizin therapy in patients with interferon-resistant chronic hepatitis C. Nippon Rinsho, 53: 1022-1025, 1995.

[56] 56. ORTIZ, V.; OLASO,V.; LOPEZ VIEDMA, B. et al. - The effect of iron depletion on the response to interferon treatment in patients with chronic hepatitis C. Pilot study. Gastroent. Hepat., 22: 122-126, 1999.

[57] 57. OTA, Y.; SASAGAWA, T.; SUZUKI, K. et al. - Vitamin E supplementation increases polyunsaturated fatty acids of RBC membrane in HCV-infected patients. Nutrition, 20: 358-363, 2004.

[58] 58. OU-YANG, P.; HWANG, L.H.; TAO, M.H.; CHIANG, B.L. & CHEN, D.S. - Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J. med. Virol., 66: 320-328, 2002.

[59] 59. PORCARO, G.; SANNINO, C.; MASTROIANNI, M. et al. - Ursodeoxycholic acid in the therapy of chronic hepatitis after treatment with interferon. Minerva med., 91: 141-145, 2000.

[60] 60. POUPON, R.E.; BONNAND, A.M.; QUENEAU, P.E. et al. - Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon. Scand. J. Gastroent., 35: 642-649, 2000.

[61] 61. PROHASKA, W. & KLEESIEK, K. - Treatment of chronic hepatitis C with inosine pranobex. Lancet, 338: 390-391, 1991.

[62] 62. RASI, G.; PIERIMARCHI,P.; SINIBALDI-VALLEBONA, P.; COLELLA, F. & GARACI, E. - Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. Immunopharmacol., 3: 1169-1176, 2003.

[63] 63. REYES-TERAN, G.; SIERRA-MADERO, J.G.; MARTINEZ DEL CERRO, V. et al. - Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. Aids, 10: 1501-1507, 1996.

[64] 64. RHODEN, E.L.; PEREIRA-LIMA,J.; RHODEN, C.R. et al. - The role of colchicine in prevention of hepatic cirrhosis induced by carbon tetrachloride. Hepatogastroenterology, 46: 1111-1115, 1999.

[65] 65. ROCKEY, D.C. - Hepatic fibrogenesis and hepatitis C. Semin. Gastrointest. Dis., 11: 69-83, 2000.

[66] 66. ROLLIER, C.; DEPLA, E.; DREXHAGE, J.A. et al. - Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J. Virol., 78: 187-196, 2004.

[67] 67. ROSSI, S.J. & WRIGHT, T.L. - New developments in the treatment of hepatitis C. Gut, 52: 756-757, 2003.

[68] 68. SARTORI, M.; ANDORNO,S.; RIGAMONTI, C. & BOLDORINI, R. - Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig. Liver Dis., 33: 157-162, 2001.

[69] 69. TAKAHARA, T.; SUGIYAMA, K.; ZHANG, L.P. et al. - Cotreatment with interferon-alpha and -gamma reduces liver fibrosis in a rat model. Hepat. Res., 28: 146-154, 2004.

[70] 70. Thalidomide and wasting. Posit. aware, 4: 5, 1995.

[71] 71. Thalidomide for diarrhea. GMHC Treat Issues, 10: 9, 1996.

[72] 72. THIBAULT, V.; DELAUGERRE, C.; CALVEZ, V. et al. - Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial. Hepatology, 35: 238-239, 2002.

[73] 73. THIELE, D.L.; DUCHARME,L.; CUNNINGHAM, M.R. et al. - Steroid therapy of chronic hepatitis: characteristics associated with response in anti-hepatitis C virus-positive and -negative patients. Amer. J. Gastroent., 91: 300-308, 1996.

[74] 74. THULUVATH, P.J.; MAHESHWARI, A.; MEHDI, J. et al. - Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut, 53: 130-135, 2004.

[75] 75. THULUVATH, P.J.; PANDE, H. & MAYGERS, J. - Combination therapy with interferon-alpha(2b), ribavirin, and amantadine in chronic hepatitis C nonresponders to interferon and ribavirin. Dig. Dis. Sci., 48: 594-597, 2003.

[76] 76. TILLMANN, H.L. & MANNS, M.P. - GB virus-C infection in patients infected with the human immunodeficiency virus. Antiviral Res., 52: 83-90, 2001.

[77] 77. TSAI, N.C.; SHIMODA, N.; WONG, L. et al. - A novel treatment of patients with chronic hepatitis C. Hawaii med. J., 58: 85-88, 1999.

[78] 78. VAN THIEL, D.H.; FARUKI, H.; FRIEDLANDER, L. et al. - Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology, 42: 907-912, 1995.

[79] 79. VERBON, A.; JUFFERMANS, N.P.; SPEELMAN, P. et al. - A single oral dose of thalidomide enhances the capacity of lymphocytes to secrete gamma interferon in healthy humans. Antimicrob. Agents Chemother., 44: 2286-2290, 2000.

[80] 80. WALKER, M.P.; APPLEBY, T.C.; ZHONG, W.; LAU, J.Y. & HONG, Z. - Hepatitis C virus therapies: current treatments, targets and future perspectives. Antivir. Chem. Chemother., 14: 1-21, 2003.

[81] 81. WRIGHT, H.I.; GAVALER, J.S.; BADDOUR, N. & VAN THIEL, D.H. - Granulocyte colony stimulating factor (G-CSF) combined with alpha-interferon for the treatment of liver allograft recipients with viral hepatitis. J. Hepat., 21: 915-916, 1994.

[82] 82. WU, K.L. & SONNEVELD, P. - Thalidomide: new uses for an old drug. Ned. Tijdschr. Geneeskd., 146: 1438-1441, 2002.

[83] 83. YOULE, M.; CLARBOUR, J.; FARTHING, C. et al. - Treatment of resistant aphthous ulceration with thalidomide in patients positive for HIV antibody. Brit. med. J., 298: 432, 1989.

[84] 84. YOUNOSSI, Z.M.; MULLEN, K.D.; HODNICK, S. et al. - Triple combination of interferon alpha-2b, ribavirin, and amantadine for treatment of chronic hepatitis C. J. clin. Gastroent., 36: 427-430, 2003.

[85] 85. ZEUZEM, S. & CARRENO, V. - Interleukin-12 in the treatment of chronic hepatitis B and C. Antiviral Res., 52: 181-188, 2001.

[86] 86. ZEUZEM, S.; HOPF, U.; CARRENO, V. et al. - A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C. Hepatology, 29: 1280-1287, 1999.

[87] 87. ZHOU, S.; LIU, R.; BAROUDY, B.M.; MALCOLM, B.A. & REYES, G.R. - The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology, 310: 333-342, 2003.

Treatment of chronic hepatitis C in non-responsive patients with pegylated interferon associated with ribavirin and thalidomide: report of six cases of total remission

Tratamento de hepatite C crônica em pacientes não respondedores, com a associação interferon peguilado, ribavirina e talidomida: Relato de seis casos

Abstracts

References

Publication Dates

History